Takeda partners with Innovent: what USD 1.20 billion means for Innovent Biologics stock

Published on 10/05/2026 at 22:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached RMB 8.618 billion in the first half of 2026, up 44.80 percent year over year. Innovent Biologics stock has 26 Buy ratings.

Innovent, KYG5420K1094, Illustration mit AI erstellt.

Takeda entered a global oncology partnership with Innovent Biologics (ISIN KYG5420K1094) on October 5, 2026, covering the development, manufacturing and commercialization of IBI363 and IBI343. According to ET Net, Innovent will receive a USD 1.20 billion upfront payment, including a USD 100.00 million equity investment by Takeda.

Deal terms reshape the pipeline

The agreement gives Takeda exclusive commercialization rights for IBI343 outside Greater China. For IBI363, the companies will share global development costs 60/40, with Takeda leading U.S. co-commercialization and holding exclusive rights outside the United States and Greater China, ET Net reports.

IBI363 is being studied in non-small cell lung and colorectal cancers, while IBI343 is being evaluated in gastric and pancreatic cancers. The transaction also grants Takeda an option on IBI3001, an early-stage program, while regulatory approvals and customary closing conditions remain part of the agreement.

Revenue growth supports the deal

Innovent reported RMB 8.618 billion of total revenue in the first half of 2026, an increase of 44.80 percent from the prior-year period. IFRS net profit reached RMB 1.253 billion, up 50.20 percent year over year, according to Futubull.

Product revenue was RMB 8.201 billion in the same period, up 56.70 percent year over year, while research and development expenses totaled RMB 1.684 billion. The figures show a business already generating commercial scale as the Takeda deal adds external funding and global development capacity.

Pipeline data set the next test

Innovent plans to present clinical data for IBI363, IBI343, IBI3001 and IBI354 at the 2026 European Society for Medical Oncology annual meeting from October 23 to October 27, 2026, according to PR Newswire. The Phase 3 IBI343 study is scheduled for a late-breaking presentation on October 23, 2026.

That calendar matters because the partnership valuation depends on clinical progress as well as commercial execution. Innovent has an established revenue base, but the late-stage oncology programs still face clinical, regulatory and launch risks before they can deliver their full economic potential.

Market value reaches HKD 169.4 billion

Innovent was valued at HKD 169.4 billion on October 5, 2026. On the Hong Kong Stock Exchange, the stock stood at HKD 97.30 at 4:08 p.m. HKT, up 1.09 percent from the prior close of HKD 96.25. The company has 26 Buy ratings and 5 Overweight ratings in the current analyst snapshot.